Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 114 от 154

Активно (без набиране) Фаза 2

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.

Начало: 13.02.2023 Край: 14.02.2028 Възраст: 12–99 г. Лечение

Australia, Brazil, Canada +12 Novartis Pharmaceuticals NCT05201066

Активно (без набиране) Фаза 3

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

High-risk Large B-cell Lymphoma (LBCL)

The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.

Начало: 10.02.2023 Край: 01.03.2031 Възраст: от 18 г. Лечение

Australia, Canada, France +8 Kite, A Gilead Company NCT05605899

Активно (без набиране) Фаза 2

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Peanut Allergy Peanut Hypersensitivity Peanut-Induced Anaphylaxis Immune System Diseases

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.

Начало: 09.02.2023 Край: 01.06.2027 Възраст: 4–17 г. Лечение

Australia, United States Aravax Pty Ltd NCT05621317

Активно (без набиране) Фаза 3

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, followed by epcoritamab or R-CHOP followed by rituximab will be explored. Approximately 900 adult participants with with newly diagnosed DLBCL will be enrolled in the study in approximately 315 sites in globally. In the Arm 1, participants will receive subcutaneous epcoritamab combined with intravenous and oral R-CHOP followed by subcutaneous epcoritamab in 21-day cycles. In the Arm 2, participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Начало: 08.02.2023 Край: 01.12.2029 Възраст: 18–79 г. Лечение

Australia, Belgium, Brazil +25 Genmab NCT05578976

Активно (без набиране) Фаза 3

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Carcinoma, Non-Small-Cell Lung

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).

Начало: 06.02.2023 Край: 23.08.2028 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +22 Merck Sharp & Dohme LLC NCT05609968

Активно (без набиране) Фаза 2

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

Huntington Disease

This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease (HD).

Начало: 03.02.2023 Край: 01.04.2027 Възраст: 25–50 г. Лечение

Argentina, Australia, Canada +9 Hoffmann-La Roche NCT05686551

Активно (без набиране) Фаза 2/3

Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children

COVID-19

Coronavirus-induced disease 2019 (COVID-19) is an infection caused by a virus whose full name is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This is a new and rapidly-spreading infectious disease which carries a significant risk of death, has brought massive economic impact globally and has proved hard to contain through public health measures. While we currently have effective vaccines, they do not protect the whole community and the constant threat of new mutations means there is an urgent need to identify new approaches to reducing community spread of infection. Heparin is a naturally occurring sugar molecule which has been used for a century to treat a range of medical problems including heart attacks, strokes, and blood clots. It has also been investigated as a treatment for pneumonias. Recent research suggests it binds to the SARS-CoV-2 virus in such a way it may reduce the virus' ability to enter cells. This may be an important way to tackle the early stages of infection which occurs inside the nose. Therefore, this medication could be used amongst people with early COVID-19 infection and amongst their household contacts to reduce the rate of virus transmission during local outbreaks. If proven effective there are many other potential uses as primary prophylaxis for people working in high risk areas, for travel, for protection in high risk crowded environments such as nightclubs, or sporting events. Heparin is safe, inexpensive, available worldwide and if effective could be rapidly used across the world to slow progression of the current pandemic. Further there are recent studies suggesting that the risk of brain complications as part of "long COVID", are directly related to the amount of virus in the nose. Reducing the viral load in the nose is thought to be effective in reducing these "long COVID" complications. This study will explore the effect of the intervention on viral load and long COVID. In this study, researchers want to investigate this medicine in people who have been identified by a COVID-19 swab test to be in the early stages of infection(defined as the index case), and amongst their household contacts. Each participant would take the medicine or a dummy control solution by spray into their nose three times a day for 10 days. The study will investigate if there are fewer people who contract SARS-CoV-2 infection by day 10 amongst households who receive the medicine than households which receive the dummy control.

Начало: 30.01.2023 Край: 01.06.2026 Възраст: 5–100 г. Превенция

Australia Murdoch Childrens Research Institute NCT05204550

Активно (без набиране)

Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease

Coronary Artery Disease

This prospective, single-arm, multi-center, safety and feasibility first-in-human study will evaluate the safety and feasibility of the SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter to treat de-novo lesions between ≥2.0 and ≤4.0 mm in patients with symptomatic stable angina, unstable angina, and NSTEMI.

Начало: 30.01.2023 Край: 01.03.2027 Възраст: 18–89 г. Лечение

Australia, Dominican Republic, New Zealand Advanced NanoTherapies NCT05521542

Активно (без набиране) Фаза 1/2

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and LBL-007 in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.

Начало: 29.01.2023 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, China, Puerto Rico +1 BeiGene NCT05609370

Активно (без набиране) Фаза 1/2

Study to Assess SLN124 in Patients With Polycythemia Vera

Polycythemia Vera

This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.

Начало: 26.01.2023 Край: 01.03.2030 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +6 Silence Therapeutics plc NCT05499013

Активно (без набиране)

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Ischemic Stroke Systemic Embolism

This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.

Начало: 25.01.2023 Край: 01.04.2032 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +6 AtriCure, Inc. NCT05478304

Активно (без набиране) Фаза 2

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Solid Tumor

The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.

Начало: 17.01.2023 Край: 31.12.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +3 Klus Pharma Inc. NCT05642780

Активно (без набиране) Фаза 3

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Melanoma

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life.

Начало: 16.01.2023 Край: 15.02.2030 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +19 Regeneron Pharmaceuticals NCT05608291

Активно (без набиране) Фаза 3

ABTECT - Maintenance

Ulcerative Colitis

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.

Начало: 16.01.2023 Край: 01.05.2030 Възраст: от 16 г. Лечение

Argentina, Australia, Belgium +29 Abivax S.A. NCT05535946

Активно (без набиране) Фаза 3

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

Начало: 12.01.2023 Край: 13.11.2028 Възраст: 18–75 г. Лечение

Argentina, Australia, Brazil +18 Bristol-Myers Squibb NCT05620407

Активно (без набиране) Фаза 1

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Endometrial Cancer High Grade Serous Adenocarcinoma of Ovary Primary Peritoneal Carcinoma Fallopian Tube Cancer +1

IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.

Начало: 11.01.2023 Край: 01.02.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +7 AbbVie NCT05527184

Активно (без набиране) Фаза 3

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Metastatic Non Small Cell Lung Cancer

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

Начало: 11.01.2023 Край: 11.05.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Daiichi Sankyo NCT05555732

Активно (без набиране) Фаза 3

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Relapsed or Refractory Multiple Myeloma

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Начало: 10.01.2023 Край: 25.07.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +22 Bristol-Myers Squibb NCT05552976

Активно (без набиране) Фаза 3

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Autosomal Dominant Hypocalcemia (ADH)

The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Начало: 06.01.2023 Край: 01.08.2029 Възраст: от 16 г. Лечение

Australia, Canada, Czechia +7 Calcilytix Therapeutics, Inc., a BridgeBio company NCT05680818

Активно (без набиране) Фаза 2

Phase 2b Study of GSK4532990 in Adults With NASH

Nonalcoholic Fatty Liver Disease Non-alcoholic Fatty Liver Disease

The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.

Начало: 02.01.2023 Край: 05.04.2027 Възраст: 18–75 г. Лечение

Argentina, Australia, Belgium +14 GlaxoSmithKline NCT05583344

1 … 112 113 114 115 116 … 154